Caitong International Asset Management’s Metagenomi Therapeutics MGX Stock Holding History

Caitong International Asset Management’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5	Buy	+4	New	+$6	﹤0.01%	2302

Other funds holding MGX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caitong International Asset Management's MGX Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Metagenomi Therapeutics (MGX) in Q1 2026: 4 shares worth $5. The stake represents ﹤0.01% of the portfolio and ranks #2302 among its holdings.

48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

Caitong International Asset Management held 4 shares of Metagenomi Therapeutics worth $5 as of Q1 2026.
Metagenomi Therapeutics was a new Caitong International Asset Management position in Q1 2026.
Metagenomi Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2302 holding.
48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.